This page uses content from Wikipedia and is licensed under CC BY-SA.

Eprobemide

Eprobemide
Eprobemide.svg
Clinical data
Trade namesBefol (RU)
Other namesBefol
Routes of
administration
Oral
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H19ClN2O2
Molar mass282.77 g/mol g·mol−1
3D model (JSmol)

Eprobemide (INN) is a pharmaceutical drug that was used as an antidepressant in Russia (under the brand name Бефол/Befol).[1] It is a non-competitive reversible inhibitor of monoamine oxidase A[2][3] that exhibits selective action on serotonin deamination.[4] Eprobemide differs from moclobemide only in the linker that connects the morpholine fragment with the chlorobenzamide — moclobemide has two carbon atoms while eprobemide has three. Its registration was cancelled on December 30, 2003.[5]

References

  1. ^ Ganellin CR, Triggle DJ (1996). Dictionary of Pharmacological Agents. 3. p. 811. ISBN 978-0412466304.
  2. ^ Gol'dina OA, Moskvitina TA, Gankina EM, Kirkel' AZ, Kamyshanskaia NS, Lopatina KI, et al. (March 1991). "[The action of befol and its derivatives on monoamine oxidase of different origins]". Biulleten' Eksperimental'noi Biologii I Meditsiny. 111 (3): 279–80. PMID 2054504.
  3. ^ Donskaya NS, Antonkina OA, Glukhan EN, Smirnov SK (2004-07-01). "Antidepressant Befol Synthesized Via Interaction of 4-Chloro-N-(3-chloropropyl)benzamide with Morpholine". Pharmaceutical Chemistry Journal. 0091-150X. 38 (7): 381–384. doi:10.1023/B:PHAC.0000048439.38383.5f.
  4. ^ "Eprobemide". ChemIDplus.
  5. ^ "Befol". 4DOKTOR.RU Drug Information Handbook (in Russian). Retrieved 4 February 2014.